Overview
Foundayo (orforglipron) is Eli Lilly’s once-daily oral GLP-1 receptor agonist, approved by the FDA on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, used alongside a reduced-calorie diet and increased physical activity.
What makes it structurally different is chemistry. Semaglutide is a peptide, which is why oral semaglutide requires careful timing around food and water for absorption. Orforglipron is a small molecule, and Lilly markets it as the only GLP-1 pill that can be taken at any time of day with no planning around food or drink. Tablets are swallowed whole and should not be broken, crushed, or chewed.
The efficacy data comes primarily from ATTAIN-1, which enrolled 3,127 adults with obesity and studied three doses — 6 mg, 12 mg and 36 mg — over 72 weeks. Lilly reported that participants taking Foundayo, regardless of trial completion, lost an average of 25 pounds (11.1%) compared with 5.3 pounds (2.1%) on placebo. Reporting on adults without type 2 diabetes described weight loss at 72 weeks of 7.9% at 6 mg, 11.3% at 12 mg and 13% at the highest dose.
Those are meaningful results for an oral agent, though they sit below what injectable tirzepatide achieves in its trials. The honest framing is that Foundayo trades some efficacy for the enormous practical advantage of being a pill you swallow with no refrigeration, no needles, no injection technique, and no timing rules. For a large group of patients, that trade is worth making — and Lilly’s launch pricing starting at $25 per month for eligible patients makes it accessible in a way brand-name injectables have never been.
What Makes Foundayo (Orforglipron) Different
A Small Molecule, Not a Peptide
Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist. That chemistry is why it can be taken at any time of day without the food and water restrictions oral semaglutide requires, and it also means it can be manufactured at scale more like a conventional tablet than a biologic.
No Refrigeration, No Needles, No Timing Rules
The practical burden of injectable GLP-1 therapy — cold-chain shipping, refrigerator space, injection technique, travel planning, sharps disposal — disappears entirely. For patients whose barrier to treatment is the injection itself rather than the medication, this changes the calculus completely.
Launch Pricing Far Below Injectable Brand-Name GLP-1s
Lilly’s launch communications put Foundayo starting at $25 per month for eligible patients, with cash pricing through channels such as GoodRx, Walgreens and Amazon Pharmacy commonly around $149 per month at entry doses. Brand-name injectable GLP-1s have never launched near those numbers.
Dose-Responsive Efficacy Across a Clear Range
ATTAIN-1 studied 6 mg, 12 mg and 36 mg, and the reported results rose with dose — approximately 7.9%, 11.3% and 13% at 72 weeks in adults without type 2 diabetes. That gives clinicians a genuine titration range to work with based on tolerability and response.
✓ Pros
- •Oral tablet, once daily – no injections at all
- •No food or water timing restrictions – unique among GLP-1 pills
- •No refrigeration required – simple storage and travel
- •FDA-approved in 2026 – full regulatory review, not compounded
- •Meaningful trial results – average 11.1% loss in ATTAIN-1, up to about 13% at higher dose
- •Launch pricing from $25/month – for eligible patients per Lilly
- •Widely distributed – LillyDirect, GoodRx, Walgreens, Amazon Pharmacy and others
- •Clear titration range – 6 mg, 12 mg and 36 mg studied in the obesity program
✗ Cons
- •Less weight loss than injectable tirzepatide – roughly 11-13% versus over 20% in Zepbound trials
- •Daily dosing – seven doses a week versus one injection, so more adherence opportunities to miss
- •GLP-1 class boxed warning applies – thyroid C-cell tumors; confirm specifics in the prescribing information
- •Gastrointestinal side effects – nausea, vomiting, diarrhea and constipation are common to the class
- •$25 pricing has eligibility conditions – most patients will pay more
- •Newly approved – less long-term real-world safety data than semaglutide or tirzepatide
- •Tablets must be swallowed whole – cannot be broken, crushed or chewed
Our #1 Recommended Provider
Foundayo is a genuine advance for patients who cannot or will not inject. If you want the lowest-cost route to GLP-1 therapy with clinical oversight included, Coreage RX remains our top overall recommendation.
Medications Offered
Brand-Name or Compounded?
Brand-name, FDA-approved. Foundayo is an FDA-approved Eli Lilly medication, approved April 1, 2026 for chronic weight management. It is not compounded, and orforglipron is not available in any compounded form — it is a patented small molecule manufactured by Lilly.
Foundayo 6 mg
From $25/month per Lilly launch pricing for eligible patientsThe lower dose studied in ATTAIN-1. Reporting on adults without type 2 diabetes described approximately 7.9% weight loss at 72 weeks at this dose.
Foundayo 12 mg
Varies by channel and dose tierThe middle dose in ATTAIN-1, with approximately 11.3% weight loss reported at 72 weeks in adults without type 2 diabetes.
Foundayo 36 mg
Varies by channel and dose tierThe highest dose studied in ATTAIN-1, with approximately 13% weight loss reported at 72 weeks in adults without type 2 diabetes.
Cash pricing through telehealth and pharmacy channels
Commonly around $149/month at entry dosesGoodRx has listed Foundayo starting at $149 per month, Amazon One Medical has been reported at roughly $149 to $299 depending on dose, and Walgreens offers it through its weight management service. LillyDirect is the manufacturer’s own channel.
Orforglipron for type 2 diabetes
Separate indication and dosingLilly has also studied orforglipron in type 2 diabetes at different doses. A 72-week diabetes study reported average weight loss of 5.1%, 7% and 9.6% across ascending doses versus 2.5% for placebo. This is a distinct indication from chronic weight management.
Foundayo’s $25 launch price carries eligibility conditions set by Lilly and is not what most patients will pay. Cash prices across telehealth and pharmacy channels commonly start around $149 per month at entry doses and rise with dose. Confirm current pricing and eligibility for your specific dose and channel before planning your budget.
Pricing, Membership & Medication Fees
| Cost Item | What You Pay |
|---|---|
| Launch pricing | Starting at $25/month per Lilly’s launch announcement, subject to eligibility conditions |
| LillyDirect | Manufacturer’s own direct channel for insured and self-pay patients |
| GoodRx | Listed from $149/month, plus GoodRx’s $39/month care membership |
| Amazon One Medical | Reported at roughly $149–$299/month cash depending on dose; from $25/month with insurance coverage |
| Walgreens Weight Management | Available through the $49-per-visit virtual service |
| knownwell | Has listed Foundayo starting at $149 |
| Compounded version | Does not exist — orforglipron is a patented small molecule |
| Insurance | Coverage depends on your plan’s formulary; prior authorization is common for this drug class |
The most important pricing fact about Foundayo is that it broke the brand-name price barrier. Where injectable brand-name GLP-1s launched near $1,000 per month, Foundayo entered the market with $25 launch pricing and cash prices around $149. That changes who can realistically access FDA-approved medication rather than compounded alternatives.
How Foundayo (Orforglipron) Works
Confirm You Are a Candidate
Foundayo is approved for chronic weight management in adults with obesity, or overweight with weight-related conditions, used alongside a reduced-calorie diet and increased physical activity. Your clinician makes this determination based on your full medical history.
Review Contraindications Carefully
GLP-1 receptor agonists as a class carry an FDA boxed warning for thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Review Foundayo’s specific prescribing information with your clinician.
Get a Prescription
Foundayo requires a prescription. You can obtain one from your own physician or through telehealth providers including GoodRx, Walgreens Weight Management, Amazon One Medical, Sesame and knownwell, each at its own consultation cost.
Choose Your Pharmacy Channel
Prices differ meaningfully by channel. LillyDirect is the manufacturer’s own route; GoodRx, Walgreens, Amazon Pharmacy and others each publish their own cash prices. Compare at your expected dose, not just the entry dose.
Take One Tablet Daily, Swallowed Whole
Foundayo is taken once daily at any time of day, with no food or water timing restrictions. Tablets must be swallowed whole and not broken, crushed or chewed. Set a consistent daily routine — daily dosing offers more opportunities to miss a dose than a weekly injection.
Titrate Under Clinical Supervision
The obesity program studied 6 mg, 12 mg and 36 mg, with results rising across that range. Your clinician will escalate based on tolerability and response. Report severe or persistent gastrointestinal symptoms rather than pushing through them.
Program Details at a Glance
| Detail | Foundayo (Orforglipron) |
|---|---|
| Consultation process | Requires a prescription from a licensed clinician. Available through your own physician or via telehealth providers including GoodRx, Walgreens Weight Management, Amazon One Medical, Sesame and knownwell. |
| Eligibility | FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related conditions, used with a reduced-calorie diet and increased physical activity. Your clinician determines suitability. |
| Provider involvement | Depends on the channel you obtain it through. Manufacturer-direct pharmacy channels provide no clinical care; telehealth platforms include varying levels of clinical support. |
| Lab requirements | Not universally required. Your clinician may order labs as part of standard evaluation and monitoring. |
| Pharmacy fulfillment | Dispensed as an FDA-approved Eli Lilly product through LillyDirect, retail pharmacies, and telehealth-partnered pharmacies. No compounded version exists. |
| Shipping frequency | Monthly supply. As an oral tablet, Foundayo does not require refrigeration or cold-chain shipping — a significant practical advantage over injectables. |
| Support services | Varies entirely by the channel you purchase through. Compare what clinical support is included when choosing a provider. |
| Membership fee | None inherent to the medication. Telehealth channels may charge their own membership or visit fees — for example GoodRx at $39/month or Walgreens at $49 per visit. |
| Medication fee | Launch pricing from $25/month for eligible patients per Lilly. Cash prices across channels commonly start around $149/month at entry doses and rise with dose. |
| Cancellation policy | Not applicable to the medication itself. Any subscription terms belong to the telehealth channel you use. |
| Refund policy | Dispensed prescription medication is generally non-returnable. |
| Insurance | Coverage depends on your plan’s formulary. Prior authorization is common for this drug class. Amazon has advertised GLP-1s from $25/month with insurance coverage. |
| HSA / FSA | Prescription medication costs are generally HSA/FSA eligible. Confirm with your plan administrator. |
| States served | Available across the United States, subject to your prescriber’s licensure and the channel’s coverage. |
Who Foundayo (Orforglipron) Is Best For
✓ Best For:
- • Patients who cannot or will not use injectable medication
- • People who travel frequently and cannot manage refrigerated medication
- • Patients with needle phobia, which is a genuine and common barrier
- • Anyone who wants FDA-approved medication rather than compounded alternatives
- • Cost-sensitive patients drawn to launch pricing and cash prices around $149
- • People who found oral semaglutide’s food and water timing rules unworkable
- • Patients seeking meaningful but not maximal weight loss with maximum convenience
✗ Not Best For:
- • Patients seeking the highest possible weight loss, where injectable tirzepatide leads
- • People with a personal or family history of medullary thyroid carcinoma or MEN 2
- • Patients who struggle with daily medication adherence and prefer weekly dosing
- • Anyone who cannot swallow tablets whole
- • Patients wanting a long real-world safety record, given the 2026 approval
- • People who cannot tolerate GLP-1 class gastrointestinal effects
Limitations to Know Before You Sign Up
- ⚠️Weight loss in the ATTAIN-1 program averaged about 11.1%, with roughly 13% at the highest studied dose. That is meaningfully less than injectable tirzepatide achieves in its trials, and patients should choose with that trade-off in view.
- ⚠️GLP-1 receptor agonists as a class carry an FDA boxed warning for thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Review Foundayo’s specific prescribing information with your clinician.
- ⚠️Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — are common across this drug class and are the leading reason patients discontinue.
- ⚠️The $25 launch price carries eligibility conditions set by Lilly. Most patients will pay cash prices closer to $149 per month at entry doses, rising with dose.
- ⚠️Daily dosing means seven opportunities a week to miss a dose rather than one. For patients whose adherence is fragile, weekly injection may paradoxically be easier.
- ⚠️Foundayo was approved in 2026, so long-term real-world safety and effectiveness data is far less extensive than for semaglutide or tirzepatide.
Alternatives to Foundayo (Orforglipron)
Wegovy Pill (Oral Semaglutide)
The other FDA-approved oral GLP-1 for weight loss, with higher reported trial weight loss but food and water timing requirements.
Mounjaro / Zepbound
Injectable tirzepatide, the highest-efficacy option currently available, if you can accept weekly injections.
LillyDirect
Eli Lilly’s manufacturer-direct channel for buying Foundayo and Zepbound.
Coreage RX
Our top-rated provider at a flat $99/month with clinical oversight included.
Frequently Asked Questions
What is Foundayo?
Foundayo (orforglipron) is Eli Lilly’s once-daily oral GLP-1 receptor agonist, approved by the FDA on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, used with a reduced-calorie diet and increased physical activity.
How much weight can you lose on Foundayo?
In the ATTAIN-1 trial of 3,127 adults with obesity, Lilly reported that participants taking Foundayo lost an average of 25 pounds (11.1%) regardless of trial completion, compared with 5.3 pounds (2.1%) on placebo. Reporting on adults without type 2 diabetes described 7.9% at 6 mg, 11.3% at 12 mg and 13% at the highest dose over 72 weeks. Individual results vary considerably.
How is Foundayo different from the Wegovy pill?
Foundayo is a small molecule; oral semaglutide is a peptide. That chemistry means Foundayo can be taken at any time of day with no food or water restrictions, while oral semaglutide has specific administration requirements around food and liquid. Oral semaglutide has reported higher trial weight loss.
How much does Foundayo cost?
Lilly’s launch communications put Foundayo starting at $25 per month for eligible patients. Cash prices across channels commonly start around $149 per month at entry doses — GoodRx has listed it from $149, Amazon One Medical at roughly $149 to $299 depending on dose, and knownwell at $149. Prices rise with dose.
Does Foundayo need to be refrigerated?
No. As an oral tablet it does not require refrigeration or cold-chain shipping, which removes a significant practical burden compared with injectable GLP-1s — particularly for travel.
What are the side effects?
Gastrointestinal effects — nausea, vomiting, diarrhea and constipation — are common across the GLP-1 class and are the most frequent reason patients stop treatment. GLP-1 receptor agonists as a class also carry an FDA boxed warning for thyroid C-cell tumors. Review the full prescribing information with your clinician.
Who should not take Foundayo?
GLP-1 receptor agonists as a class are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Other contraindications and precautions apply — this is a decision only your clinician can make with your full history.
Is there a compounded version of orforglipron?
No. Orforglipron is a patented small molecule manufactured by Eli Lilly and is not available in compounded form. Any product marketed as compounded orforglipron should be treated with serious caution.
The Bottom Line
Foundayo earns 4.5 out of 5 stars for solving the single biggest practical barrier in this category. A once-daily tablet with no injections, no refrigeration, no cold-chain shipping and no food or water timing rules removes essentially every logistical obstacle that keeps people from starting or staying on GLP-1 therapy — and it does so as a fully FDA-approved medication rather than a compounded workaround.
The efficacy is genuinely respectable for an oral agent. An average of 11.1% weight loss in ATTAIN-1, rising to about 13% at the highest studied dose in adults without type 2 diabetes, is a clinically meaningful result that comfortably exceeds the 5% threshold associated with metabolic benefit. It is not tirzepatide-level, and patients seeking maximum weight loss should know that going in.
The pricing story may matter as much as the clinical one. Lilly launched Foundayo at $25 per month for eligible patients, with cash prices across channels commonly around $149 — numbers that no brand-name injectable GLP-1 has ever approached at launch. That opens FDA-approved medication to patients who would otherwise be choosing between compounded alternatives and nothing at all.
Our recommendation: Foundayo is the right first choice for anyone whose barrier is the injection itself, who travels frequently, or who wants FDA-approved medication at an accessible price. If you want maximum weight loss and can accept weekly injections, tirzepatide remains more effective. If you want the lowest all-in monthly cost with clinical oversight bundled in, Coreage RX at $99/month is our top overall pick. To buy Foundayo direct from the manufacturer, see LillyDirect.
Disclosure:
This review is based on publicly available information including Eli Lilly’s own product and investor communications, the ATTAIN-1 trial reporting, peer-reviewed publication summaries, Drugs.com, GoodRx and independent clinical news coverage, current as of August 24, 2026. Presidential GLP-1 may receive compensation from some providers featured on this site, which helps us provide free, independent reviews; we do not have a compensation relationship with Eli Lilly. Trial results describe average outcomes under study conditions and individual results vary substantially. Launch pricing carries eligibility conditions set by the manufacturer and is subject to change. This page summarizes publicly reported information and is not a substitute for the FDA-approved prescribing information, which you should review with your clinician. We do not sell, dispense, or ship medication.
⚕️ Medical Disclaimer:
This review is for informational purposes only and is not medical advice, diagnosis, or treatment. GLP-1 receptor agonists are prescription medications with serious risks and contraindications, including a boxed warning for thyroid C-cell tumors. Only a licensed clinician who knows your medical history can determine whether any weight-management medication is appropriate for you. Never start, stop, or change a prescription based on this page. If you experience severe abdominal pain, persistent vomiting, signs of an allergic reaction, or other concerning symptoms, seek medical care immediately. See our full medical disclaimer.
Or check out our top-rated provider